Top

Published in:

01-04-2007 | Original Article

Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms

Authors: E. Compérat, P. Camparo, R. Haus, E. Chartier-Kastler, B. Radenen, F. Richard, F. Capron, V. Paradis

Published in: Virchows Archiv | Issue 4/2007

Abstract

Aurora-A, a member of serine/threonine kinase, is implied in mitosis and centrosome maturation. Increasing levels of Aurora-A have been shown to be present in several malignancies and especially in bladder cancer. No immunohistochemical marker has shown to be able to predict the clinical outcome of patients with superficial bladder cancer, except MIB-1, as a predictive marker of relapse and progression. The aim was to investigate the expression of Aurora-A and MIB-1 in tissue micro arrays of superficial bladder cancer representative of pTa papillary urothelial neoplasm with different degrees of aggressiveness (low malignant potential [PUNLMP], non-invasive papillary urothelial carcinoma low grade [NILGC], non-invasive papillary urothelial carcinoma high grade [NIHGC] and carcinoma in situ). We analysed predictive values of both markers, their specificity and sensitivity in tumor recurrence. Aurora-A was a sensitive marker to predict tumor recurrence especially for pTa (PUNLMP, NILGC; PUNLMP p < 0.001, NILGC p < 0.001) with statistical significant correlation between immunohistochemical staining and clinical outcome. MIB-1 expression displayed statistical difference p = 0.002 in the PUNLMP group and p = 0.03 in the NILGC group. Aurora-A is a more sensitive marker than MIB-1 to predict relapse in pTa bladder neoplasias. The combination of both markers seems to have a very powerful predictive value of recurrence (p < 0.001).

Alsheikh A, Mohamedali Z, Jones E, Masterson J, Gilks CB (2001) Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/International Society of Urologic Pathology. Mod Pathol 14(4):267–272PubMedCrossRef

Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD et al (1998) Mutations of mitotic checkpoint genes in human cancers. Nature 392(6673):300–303PubMedCrossRef

Chopin DK, Gattegno B (2002) Superficial bladder tumors. Eur Urol 42(6):533–541PubMedCrossRef

Ducat D, Zheng Y (2004) Aurora kinases in spindle assembly and chromosome segregation. Exp Cell Res 301(1):60–67PubMedCrossRef

Duchrow M, Schluter C, Wohlenberg C, Flad HD, Gerdes J (1996) Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67. Cell Prolif 29(1):1–12PubMedCrossRef

Dybowski B, Kupryjanczyk J, Rembiszewska A, Pykalo R, Borkowski A (2003) P27(Kip1) and Ki-67 expression analysis in transitional cell carcinoma of the bladder. Urol Res 31(6):397–401PubMedCrossRef

Dyrskjot L, Zieger K, Kruhoffer M, Thykjaer T, Jensen JL, Primdahl H et al (2005) A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 11(11):4029–4036PubMedCrossRef

Eble JN, Sauter G, Epstein JI, Sesterhenn IA (2004) Tumours of the urinary system and male genital organs. IARC, Lyon, France

Fraizer GC, Diaz MF, Lee IL, Grossman HB, Sen S (2004) Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. Int J Oncol 25(6):1631–1639PubMed

10.

Frank I, Cheville JC, Blute ML, Lohse CM, Karnes RJ, Weaver AL et al (2004) Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement. Cancer 101(8):1803–1808PubMedCrossRef

11.

Gattegno B, Chopin D (2001) Natural history of superficial bladder tumors. Prog Urol 11(5):963–990PubMed

12.

Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA et al (2003) Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 9(4):1420–1426PubMed

13.

Helpap B (2001) Nonepithelial neoplasms of the urinary bladder. Virchows Arch 439(4):497–503PubMedCrossRef

14.

Helpap B, Schmitz-Drager BJ, Hamilton PW, Muzzonigro G, Galosi AB, Kurth KH et al (2003) Molecular pathology of non-invasive urothelial carcinomas (part I). Virchows Arch 442(4):309–316PubMed

15.

Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL (2001) Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 165(4):1124–1128, discussion 1128–1130PubMedCrossRef

16.

Holmang S, Johansson SL (2002) Stage Ta-T1 bladder cancer: the relationship between findings at first follow-up cystoscopy and subsequent recurrence and progression. J Urol 167(4):1634–1637PubMedCrossRef

17.

Jeng YM, Peng SY, Lin CY, Hsu HC (2004) Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 10(6):2065–2071PubMedCrossRef

18.

Jourdan F, Sebbagh N, Comperat E, Mourra N, Flahault A, Olschwang S et al (2003) Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch 443(2):115–121PubMedCrossRef

19.

Kamada K, Yamada Y, Hirao T, Fujimoto H, Takahama Y, Ueno M et al (2004) Amplification/overexpression of Aurora-A in human gastric carcinoma: potential role in differentiated type gastric carcinogenesis. Oncol Rep 12(3):593–599PubMed

20.

Knowles MA (2001) What we could do now: molecular pathology of bladder cancer. Mol Pathol 54(4):215–221PubMedCrossRef

21.

Lebret T, Bohin D, Kassardjian Z, Herve JM, Molinie V, Barre P et al (2000) Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette–Guerin instillations. J Urol 163(1):63–67PubMedCrossRef

22.

Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K et al (2003) Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 9(3):991–997PubMed

23.

Mai KT, Elmontaser G, Perkins DG, Yazdi HM, Stinson WA, Thijssen A (2004) Histopathological and immunohistochemical study of papillary urothelial neoplasms of low malignant potential and grade associated with extensive invasive low-grade urothelial carcinoma. BJU Int 94(4):544–547PubMedCrossRef

24.

Nocito A, Bubendorf L, Maria Tinner E, Suess K, Wagner U, Forster T et al (2001) Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 194(3):349–357PubMedCrossRef

25.

Reis-Filho JS, Simpson PT, Martins A, Preto A, Gartner F, Schmitt FC (2003) Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch 443(2):122–132PubMedCrossRef

26.

Richter J, Jiang F, Gorog JP, Sartorius G, Egenter C, Gasser TC et al (1997) Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 57(14):2860–2864PubMed

27.

Sanchez-Carbayo M (2004) Recent advances in bladder cancer diagnostics. Clin Biochem 37(7):562–571PubMedCrossRef

28.

Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S et al (2002) Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94(17):1320–1329PubMed

29.

Shariat SF, Kim J, Raptidis G, Ayala GE, Lerner SP (2003) Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 61(6):1140–1145PubMedCrossRef

30.

Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT et al (1999) p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398(6729):714–718PubMedCrossRef

Title: Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms
Authors: E. Compérat
P. Camparo
R. Haus
E. Chartier-Kastler
B. Radenen
F. Richard
F. Capron
V. Paradis
Publication date: 01-04-2007
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 4/2007
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-007-0383-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2007

Cytological diagnosis of malignant mesothelioma—improvement by additional analysis of hyaluronic acid in pleural effusions

Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer

Perivascular epithelioid cell neoplasms (PEComas): four malignant cases expanding the histopathological spectrum and a description of a unique finding

Expression of sex steroid hormone receptors in C cell hyperplasia and medullary thyroid carcinoma

Multicentric invasive carcinomas derived from intraductal papillary mucinous neoplasm (IPMN) of the pancreas: report of a case

Expression of the breast differentiation antigen NY-BR-1 in a phyllodes tumor of the vulva